ProCE Banner Activity

ExpressPoints: HER2-Positive Breast Cancer: A Guide Through an Evolving Treatment Landscape

Slideset Download
Download this short summary slideset on current optimal treatment for patients with HER2-positive breast cancer.

Released: February 09, 2021

Expiration: February 08, 2022

No longer available for credit.

Share

Faculty

Jame Abraham

Jame Abraham, MD, FACP

Chairman
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland Clinic
Cleveland, Ohio

Hope S. Rugo

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Jame Abraham, MD, FACP

Chairman
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland Clinic
Cleveland, Ohio

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts